文献速递乳腺癌

基于内在亚型的乳腺癌监督式风险预测模型

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.
PubMed 文献 · J Clin Oncol · 2023-01-01

研究利用189例原型样本的微阵列和定量逆转录聚合酶链反应数据开发了50基因亚型预测器,在761例未接受全身治疗的患者中评估预后,在133例患者中评估对新辅助紫杉类和蒽环类方案病理完全缓解(pCR)的预测。内在亚型具有预后意义(P=2.26E-12),联合模型(亚型+肿瘤大小)的C指数显著优于临床病理模型或亚型模型单独;内在亚型模型预测pCR的阴性预测值为97%。结论认为内在亚型诊断可为乳腺癌标准参数增加显著的预后和预测信息。

要点

  • 50基因内在亚型预测器在761例未接受全身治疗患者中显示预后意义(P=2.26E-12)。
  • 联合模型(亚型+肿瘤大小)C指数显著优于临床病理模型或亚型模型单独。
  • 内在亚型模型预测新辅助化疗pCR的阴性预测值为97%。

核心结论

  • 基于内在亚型的诊断可为乳腺癌患者的标准参数增加显著的预后和预测信息。
  • 连续风险评分的预后特性对淋巴结阴性乳腺癌的管理有价值。
  • 亚型和风险评分可用于评估新辅助化疗疗效的可能性。

研究设计与样本

  • 利用189例原型样本的微阵列和定量逆转录聚合酶链反应数据开发50基因亚型预测器。
  • 在761例未接受全身治疗的患者中评估预后。
  • 在133例患者中评估对紫杉类和蒽环类方案病理完全缓解(pCR)的预测。

主要发现

  • 内在亚型作为离散实体显示预后意义(P=2.26E-12),在纳入标准参数(雌激素受体状态、组织学分级、肿瘤大小和淋巴结状态)的多变量分析中仍显著。
  • 使用内在亚型和临床信息构建了淋巴结阴性乳腺癌的预后模型。
  • 联合模型(亚型+肿瘤大小)的C指数估计显著优于临床病理模型或亚型模型单独。
  • 内在亚型模型预测新辅助化疗疗效的pCR阴性预测值为97%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression-based "intrinsic" subtypes luminal A, luminal B, HER2-enriched, and basal-like. METHODS: A 50-gene subtype predictor was developed using microarray and quantitative reverse transcriptase polymerase chain reaction data from 189 prototype samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen. RESULTS: The intrinsic subtypes as discrete entities showed prognostic significance (P = 2.26E-12) and remained significant in multivariable analyses that incorporated standard parameters (estrogen receptor status, histologic grade, tumor size, and node status). A prognostic model for node-negative breast cancer was built using intrinsic subtype and clinical information. The C-index estimate for the combined model (subtype and tumor size) was a significant improvement on either the clinicopathologic model or subtype model alone. The intrinsic subtype model predicted neoadjuvant chemotherapy efficacy with a negative predictive value for pCR of 97%. CONCLUSION: Diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer. The prognostic properties of the continuous risk score will be of value for the management of node-negative breast cancers. The subtypes and risk score can also be used to assess the likelihood of efficacy from neoadjuvant chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Parker JS, Mullins M, Cheang MCU, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol. 2023. PMID: 37672882. doi:10.1200/JCO.22.02511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。